Should I buy or sell Eli Lilly and Company stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There are currently 1 sell rating, 2 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LLY shares. View LLY analyst ratings or view top-rated stocks .

What is Eli Lilly and Company's stock price target for 2024?

19 brokerages have issued 1 year target prices for Eli Lilly and Company's stock. Their LLY share price targets range from $278.00 to $865.00. On average, they expect the company's share price to reach $621.81 in the next twelve months. This suggests that the stock has a possible downside of 15.5%. View analysts price targets for LLY or view top-rated stocks among Wall Street analysts .

How have LLY shares performed in 2024?

Eli Lilly and Company's stock was trading at $582.92 at the beginning of the year. Since then, LLY shares have increased by 26.2% and is now trading at $735.68. View the best growth stocks for 2024 here .

When is Eli Lilly and Company's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our LLY earnings forecast .

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) posted its quarterly earnings results on Tuesday, February, 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm earned $9.35 billion during the quarter, compared to analysts' expectations of $8.95 billion. Eli Lilly and Company had a trailing twelve-month return on equity of 50.78% and a net margin of 15.36%. Eli Lilly and Company's revenue was up 28.1% compared to the same quarter last year. During the same period last year, the firm posted $2.09 EPS. Read the conference call transcript .

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company declared a quarterly dividend on Friday, December 8th. Stockholders of record on Thursday, February 15th will be paid a dividend of $1.30 per share on Friday, March 8th. This represents a $5.20 annualized dividend and a yield of 0.71%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from the stock's previous quarterly dividend of $1.13. Read our dividend analysis for LLY .

Is Eli Lilly and Company a good dividend stock?

Eli Lilly and Company (NYSE:LLY) pays an annual dividend of $4.52 per share and currently has a dividend yield of 0.64%. The company has been increasing its dividend for 10 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 77.93%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, LLY will have a dividend payout ratio of 25.41% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for LLY .

What ETFs hold Eli Lilly and Company's stock?

ETFs with the largest weight of Eli Lilly and Company (NYSE:LLY) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE) , Harbor Health Care ETF (MEDI) , Invesco S&P 500 Momentum ETF (SPMO) , Horizon Kinetics Medical ETF (MEDX) , Goldman Sachs Future Health Care Equity ETF (GDOC) , iShares U.S. Healthcare ETF (IYH) , Health Care Select Sector SPDR Fund (XLV) and Vanguard Health Care ETF (VHT) .

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company updated its FY24 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of $12.20-12.70 for the period, compared to the consensus earnings per share estimate of $12.39. The company issued revenue guidance of $40.4-41.6 billion, compared to the consensus revenue estimate of $39.27 billion.

What is David A. Ricks' approval rating as Eli Lilly and Company's CEO?

399 employees have rated Eli Lilly and Company Chief Executive Officer David A. Ricks on Glassdoor.com . David A. Ricks has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Eli Lilly and Company own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and Company investors own include Johnson & Johnson (JNJ) , Pfizer (PFE) , NVIDIA (NVDA) , Intel (INTC) , Cisco Systems (CSCO) , Bristol-Myers Squibb (BMY) , Walt Disney (DIS) , AT&T (T) , Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM) .

Who are Eli Lilly and Company's major shareholders?

Eli Lilly and Company's stock is owned by a variety of retail and institutional investors. Top institutional investors include Jennison Associates LLC (0.80%), International Assets Investment Management LLC (0.77%), Charles Schwab Investment Management Inc. (0.48%), Fisher Asset Management LLC (0.48%), Dimensional Fund Advisors LP (0.36%) and Massachusetts Financial Services Co. MA (0.34%). Insiders that own company stock include Acquisition Corp Kearny, Alonzo Weems , Anne E White , Donald A Zakrowski , Ilya Yuffa , Jackson P Tai , Johna Norton , Lilly Endowment Inc, Marschall S Runge and Patrik Jonsson. View institutional ownership trends .

How do I buy shares of Eli Lilly and Company?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Eli Lilly and Company have any subsidiaries?

The following companies are subsidiares of Eli Lilly and Company: 1096401 B.C. Unlimited Liability Company, ARMO Biosciences Inc., Acanthas Pharma Inc., Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma Inc., Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Compania Farmaceutica Eli Lilly de Centro America S.A., Dermira, Dermira Canada, Dermira Inc., Devices for Vascular Intervention(DVI), Disarm Therapeutics, Disarm Therapeutics, Disarm Therapeutics Inc., Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc., Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, LDH I Corporation, Lilly (Shanghai) Management Co. Ltd., Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly Centre for Clinical Pharmacology PTE. LTD., Lilly China Research and Development Co. Ltd, Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Loxo Oncology Inc., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Petra Pharma Corporation, Pharmaserve-Lilly S.A.C.I., Pharmaserve-Lilly S.A.C.I., Physio-Control, Prevail Therapeutics Inc., Protomer Technologies, SGX Pharmaceuticals, SGX Pharmaceuticals Inc., Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos. Read More

Followed 122 TimesTop Followed

NYSE:LLY

Eli Lilly and Company (LLY) Stock Price, News & Analysis

→ Gold explodes past $2,000, here's what's next (From Stansberry Research) (Ad)

Free LLY Stock Alerts

$735.56

+10.17 (+1.40%)

(As of 02/8/2024 ET)

Compare

Today's Range: $725.97
▼
$740.77
50-Day Range: $570.21
▼
$724.91
52-Week Range: $309.20
▼
$742.00

Volume: 4.64 million shs
Average Volume: 3.47 million shs
Market Capitalization: $698.27 billion

P/E Ratio: 126.82
Dividend Yield: 0.61%
Price Target: $621.81

Get Eli Lilly and Company alerts:

Eli Lilly and Company MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.79 Rating Score
Upside/Downside: 15.5% Downside
$621.81 Price Target
Short Interest: Healthy
0.58% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: -2.25
Upright™ Environmental Score
News Sentiment: 0.49
Based on 88 Articles This Week
Insider Trading: Selling Shares
$125.25 M Sold Last Quarter
Proj. Earnings Growth: 39.75%
From $12.73 to $17.79 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.72 out of 5 stars

Medical Sector

54th out of 911 stocks

Pharmaceutical Preparations Industry

18th out of 424 stocks

2.4

Analyst's Opinion

Consensus Rating
Eli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 16 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $621.81, Eli Lilly and Company has a forecasted downside of 15.5% from its current price of $735.68.
Amount of Analyst Coverage
Eli Lilly and Company has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
0.58% of the float of Eli Lilly and Company has been sold short.
Short Interest Ratio / Days to Cover
Eli Lilly and Company has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Eli Lilly and Company has recently decreased by 3.93%, indicating that investor sentiment is improving.

2.5

Dividend Strength

Dividend Yield
Eli Lilly and Company has a dividend yield of 0.64%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Eli Lilly and Company has been increasing its dividend for 10 years.
Dividend Coverage
The dividend payout ratio of Eli Lilly and Company is 77.93%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 25.41% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Eli Lilly and Company has received a 56.49% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Peptide analogs", "Pemetrexed", "Insulin", and "SGLT2 inhibitors" products. See details.
Environmental Sustainability
The Environmental Impact score for Eli Lilly and Company is -2.25.

3.0

News and Social Media Coverage

News Sentiment
Eli Lilly and Company has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 88 news articles for Eli Lilly and Company this week, compared to 30 articles on an average week.
Search Interest
219 people have searched for LLY on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.
MarketBeat Follows
121 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eli Lilly and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $125,254,657.00 in company stock.
Percentage Held by Insiders
Only 0.13% of the stock of Eli Lilly and Company is held by insiders.
Percentage Held by Institutions
81.38% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Eli Lilly and Company are expected to grow by 39.75% in the coming year, from $12.73 to $17.79 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eli Lilly and Company is 126.84, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 125.82.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eli Lilly and Company is 126.84, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 94.87.
Price to Earnings Growth Ratio
Eli Lilly and Company has a PEG Ratio of 2.24. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Eli Lilly and Company has a P/B Ratio of 64.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

Here's the next stock we think soars >>>

About Eli Lilly and Company Stock (NYSE:LLY)

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

LLY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LLY Stock News Headlines

February 7, 2024 | marketbeat.com

Eli Lilly's formula for success: Blending innovation with insight

Eli Lilly showcases its financial strength and strategic innovation through its Q4 2023 earnings and forward-looking growth initiatives.

February 6, 2024 | marketbeat.com

Weight loss, diabetes drugs propel Eli Lilly to better-than-expected forecast for 2024

The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth-quarter forecasts, and the drugmaker expects 2024 to turn out largely better than expected too, as new products build momentum

February 8, 2024 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

February 5, 2024 | marketbeat.com

Markets suddenly price Eli Lilly stock for a breakout on earnings (LLY)

The healthcare sector could see a sudden inflow of investment dollars, and Eli Lilly quickly becomes a favorite name in the space as markets and analysts bid up

January 29, 2024 | marketbeat.com

Pfizer’s earnings growth trade at a deep discount, suddenly a buy (LLY)

The healthcare sector is set to attract a new inflow of investment dollars, as seen in business activity and employment. Pfizer is the clear sector favorite

January 25, 2024 | marketbeat.com

5 top healthcare stocks for earnings growth in 2024 (LLY)

2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.

January 19, 2024 | marketbeat.com

20 best healthcare dividend stocks to invest in (LLY)

Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.

January 18, 2024 | marketbeat.com

Merck, the Dow's hottest stock, gets set to report Q4 financials (LLY)

Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks.

February 8, 2024 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

January 16, 2024 | marketbeat.com

2 biotechs with promising weight-loss drugs coming (LLY)

Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co.

January 11, 2024 | marketbeat.com

AstraZeneca: Rebound in 2024 with double-digit earnings growth (LLY)

AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition

January 9, 2024 | marketbeat.com

Where will S&P 500 go after new bullish levels? (LLY)

Major indexes look resilient despite 2024's rocky start, getting support at key moving averages. Upcoming earnings could be catalysts in either direction.

February 8, 2024 | msn.com

Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month

February 8, 2024 | marketwatch.com

Viking Therapeutics may offer investors a cheap entry to the weight-loss drug craze

February 8, 2024 | finance.yahoo.com

Eli Lilly and Company (NYSE:LLY) Analysts Are Pretty Bullish On The Stock After Recent Results

February 8, 2024 | fool.com

4 Reasons Why 2024 Could Be Eli Lilly's Worst Year for the Rest of This Decade

February 8, 2024 | seekingalpha.com

Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade)

February 8, 2024 | finance.yahoo.com

Eli Lilly and Company: Raising target price to $770

February 7, 2024 | finance.yahoo.com

Liver Disease Biotechs’ Stocks Crash on Eli Lilly’s Mounjaro Data

February 7, 2024 | thestreet.com

Analysts revamp Eli Lilly stock price target on weight-loss drugs

February 7, 2024 | seekingalpha.com

Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade)

February 7, 2024 | markets.businessinsider.com

Eli Lilly: Strong Q4 Performance and Promising Tirzepatide Trials Justify Buy Rating

February 7, 2024 | msn.com

Minnesota and Eli Lilly settle insulin price-gouging lawsuit. Deal will hold costs to $35 a month

February 7, 2024 | forbes.com

Forbes Daily: Weight Loss Drugs Fuel Eli Lilly’s Ascent

February 7, 2024 | msn.com

Eli Lilly Stock Rises. Earnings Were Boosted by Obesity Drug Sales.

February 7, 2024 | finance.yahoo.com

Eli Lilly and Company (NYSE:LLY) Q4 2023 Earnings Call Transcript

February 7, 2024 | americanbankingnews.com

Eli Lilly and Company (NYSE:LLY) Price Target Increased to $825.00 by Analysts at Wells Fargo & Company

See More Headlines

Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 12/8 Dividend: 11/14/2023
Dividend Payable: 12/08/2023
Last Earnings: 2/06/2024
Today: 2/08/2024
Ex-Dividend for 3/8 Dividend: 2/14/2024
Dividend Payable: 3/08/2024
Next Earnings (Estimated): 4/25/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NYSE:LLY
CUSIP: 53245710
CIK: 59478
Web: www.lilly.com
Phone: (317) 276-2000
Fax: 317-276-4878
Employees: 39,000
Year Founded: 1876

Price Target and Rating

Average Stock Price Target: $621.81
High Stock Price Target: $865.00
Low Stock Price Target: $278.00
Potential Upside/Downside: -15.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.79
Research Coverage: 19 Analysts

Profitability

EPS (Most Recent Fiscal Year): $5.80
Trailing P/E Ratio: 126.84
Forward P/E Ratio: 57.79
P/E Growth: 2.24
Net Income: $6.24 billion
Net Margins: 15.36%
Pretax Margin: 19.21%
Return on Equity: 50.78%
Return on Assets: 10.33%

Debt

Debt-to-Equity Ratio: 1.59
Current Ratio: 1.05
Quick Ratio: 0.82

Sales & Book Value

Annual Sales: $34.12 billion
Price / Sales: 20.47
Cash Flow: $9.56 per share
Price / Cash Flow: 76.92
Book Value: $11.34 per share
Price / Book: 64.87

Miscellaneous

Outstanding Shares: 949,310,000
Free Float: 948,073,000
Market Cap: $698.39 billion
Optionable: Optionable
Beta: 0.32

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. David A. Ricks (Age 56)
Chairman, CEO & President
Comp: $4.42M
Ms. Anat Ashkenazi (Age 51)
Executive VP & CFO
Comp: $2.13M
Dr. Daniel M. Skovronsky M.D. (Age 51)
Ph.D., EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology
Comp: $2.72M
Ms. Anat Hakim J.D. (Age 55)
Executive VP, General Counsel & Secretary
Comp: $1.98M
Mr. Patrik Jonsson (Age 57)
EVP, Chief Customer Officer, President of Lilly Diabetes & Obesity and President Lilly USA
Comp: $1.67M
Mr. Donald A. Zakrowski
Chief Accounting Officer & VP of Finance
Mr. Diogo Rau
EVP & Chief Information and Digital Officer
Mr. Alonzo Weems (Age 53)
EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer
Mr. Eric Dozier (Age 57)
Executive Vice President of Human Resources & Diversity
Mr. Jeffrey N. Simmons (Age 57)
Senior VP & President of Elanco Animal Health
Comp: $1.73M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LLY Stock Analysis - Frequently Asked Questions

Should I buy or sell Eli Lilly and Company stock right now?: 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There are currently 1 sell rating, 2 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LLY shares.
View LLY analyst ratings or view top-rated stocks.
What is Eli Lilly and Company's stock price target for 2024?: 19 brokerages have issued 1 year target prices for Eli Lilly and Company's stock. Their LLY share price targets range from $278.00 to $865.00. On average, they expect the company's share price to reach $621.81 in the next twelve months. This suggests that the stock has a possible downside of 15.5%.
View analysts price targets for LLY or view top-rated stocks among Wall Street analysts.
How have LLY shares performed in 2024?: Eli Lilly and Company's stock was trading at $582.92 at the beginning of the year. Since then, LLY shares have increased by 26.2% and is now trading at $735.68.
View the best growth stocks for 2024 here.
When is Eli Lilly and Company's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our LLY earnings forecast.
How were Eli Lilly and Company's earnings last quarter?: Eli Lilly and Company (NYSE:LLY) posted its quarterly earnings results on Tuesday, February, 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm earned $9.35 billion during the quarter, compared to analysts' expectations of $8.95 billion. Eli Lilly and Company had a trailing twelve-month return on equity of 50.78% and a net margin of 15.36%. Eli Lilly and Company's revenue was up 28.1% compared to the same quarter last year. During the same period last year, the firm posted $2.09 EPS.
Read the conference call transcript.
How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?: Eli Lilly and Company declared a quarterly dividend on Friday, December 8th. Stockholders of record on Thursday, February 15th will be paid a dividend of $1.30 per share on Friday, March 8th. This represents a $5.20 annualized dividend and a yield of 0.71%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from the stock's previous quarterly dividend of $1.13.
Read our dividend analysis for LLY.
Is Eli Lilly and Company a good dividend stock?: Eli Lilly and Company (NYSE:LLY) pays an annual dividend of $4.52 per share and currently has a dividend yield of 0.64%. The company has been increasing its dividend for 10 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 77.93%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, LLY will have a dividend payout ratio of 25.41% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.
What ETFs hold Eli Lilly and Company's stock?: ETFs with the largest weight of Eli Lilly and Company (NYSE:LLY) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Harbor Health Care ETF (MEDI), Invesco S&P 500 Momentum ETF (SPMO), Horizon Kinetics Medical ETF (MEDX), Goldman Sachs Future Health Care Equity ETF (GDOC), iShares U.S. Healthcare ETF (IYH), Health Care Select Sector SPDR Fund (XLV) and Vanguard Health Care ETF (VHT).

What guidance has Eli Lilly and Company issued on next quarter's earnings?: Eli Lilly and Company updated its FY24 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of $12.20-12.70 for the period, compared to the consensus earnings per share estimate of $12.39. The company issued revenue guidance of $40.4-41.6 billion, compared to the consensus revenue estimate of $39.27 billion.
What is David A. Ricks' approval rating as Eli Lilly and Company's CEO?: 399 employees have rated Eli Lilly and Company Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.
What other stocks do shareholders of Eli Lilly and Company own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and Company investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).
Who are Eli Lilly and Company's major shareholders?: Eli Lilly and Company's stock is owned by a variety of retail and institutional investors. Top institutional investors include Jennison Associates LLC (0.80%), International Assets Investment Management LLC (0.77%), Charles Schwab Investment Management Inc. (0.48%), Fisher Asset Management LLC (0.48%), Dimensional Fund Advisors LP (0.36%) and Massachusetts Financial Services Co. MA (0.34%). Insiders that own company stock include Acquisition Corp Kearny, Alonzo Weems, Anne E White, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Johna Norton, Lilly Endowment Inc, Marschall S Runge and Patrik Jonsson.
View institutional ownership trends.
How do I buy shares of Eli Lilly and Company?: Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Eli Lilly and Company have any subsidiaries?: The following companies are subsidiares of Eli Lilly and Company: 1096401 B.C. Unlimited Liability Company, ARMO Biosciences Inc., Acanthas Pharma Inc., Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma Inc., Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Compania Farmaceutica Eli Lilly de Centro America S.A., Dermira, Dermira Canada, Dermira Inc., Devices for Vascular Intervention(DVI), Disarm Therapeutics, Disarm Therapeutics, Disarm Therapeutics Inc., Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc., Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, LDH I Corporation, Lilly (Shanghai) Management Co. Ltd., Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly Centre for Clinical Pharmacology PTE. LTD., Lilly China Research and Development Co. Ltd, Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Loxo Oncology Inc., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Petra Pharma Corporation, Pharmaserve-Lilly S.A.C.I., Pharmaserve-Lilly S.A.C.I., Physio-Control, Prevail Therapeutics Inc., Protomer Technologies, SGX Pharmaceuticals, SGX Pharmaceuticals Inc., Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More

This page (NYSE:LLY) was last updated on 2/8/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Eli Lilly and Company (LLY) Stock Price, News & Analysis

Eli Lilly and Company MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Eli Lilly and Company Stock (NYSE:LLY)

LLY Stock Price History

LLY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

LLY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™